SBIR/STTR Research Award

MycoMEIA - Urine Diagnostic for Aspergillosis

Award identifier 0503d2075d388597cea4f01d3ef989170e8f1611483826550e81cdbd4aaf2e51Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$976,576

Program and phase

SBIR · Phase II – Direct to Phase II

Award year

2021

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
PEARL DIAGNOSTICS, INC.
Proposal award date
2021-03-08
Contract end date
2022-02-28
UEI
N9CGVFYJM1B5
Solicitation number
PA19-272
Topic code
NIAID

Research abstract

Aspergillosis causes morbidity and death in medically immune compromised patients, especially after cancer chemotherapy and transplant. Recently, we have witnessed increased cases of influenza-associated aspergillosis and COVID-19-associated aspergillosis, complicating effective treatment in those critically ill with viral infections. Outcomes are poor in part because we lack sensitive diagnostic tests that are easy to use during high-risk periods. During our efforts to develop easier diagnostic tests, we discovered that fungal galactofuranose (galf)– containing antigens are excreted in urine of infected animals and people, using novel monoclonal antibodies. We engineered a prototype enzyme immunoassay called MycoMEIA, and performance was tested using urine samples obtained from patients with suspected and confirmed IA. Results showed andgt;80% sensitivity and specificity, meeting predefined metrics for clinical study. As part of this proposal, this design-locked assay will move into clinical study, in three clinical microbiology laboratories to support FDA 510k application. Additional work is proposed to understand how the urine assay can be optimized to detect aspergillosis in non-hematology patients at risk, including ICU patients with COVID-19. Success in meeting the milestones described will lead to commercial availability of the first rapid, easy to use urine diagnostic assay for this important fungal infection, with potential to reduce disease prevalence and improve outcomes.Invasive aspergillosis is a fungal disease caused by the inhalation of fungal spores that are present in our environment. People with weakened immune systems caused by cancer, lung diseases and other conditions are at a high risk of developing pneumonia caused by these environmental organisms. Fungal spores can grow within the lung rather quickly resulting in invasive disease, which has a high percentage of deaths. We have developed a rapid, easy to use urine test to detect the fungus in the body, which will be useful to prevent infection and to start appropriate medications for therapy.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

5 SBIR/STTR records share this UEI (2015–2025). Reported award amounts total $4,208,302. Reported amounts are not federal obligations.

Phases: Phase II, Phase I, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services, National Science Foundation

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.